Member Info for B2HS2L

quercu,
Observation from your link:

Prof Knut Wittkowski:
"With all respiratory diseases, the only thing that stops the disease is herd immunity. About 80% of the people need to have had contact with the virus, and the majority of them won’t even have recognized that they were infected, or they had very, very mild symptoms, especially if they are children. So, it’s very important to keep the schools open and kids mingling to spread the virus to get herd immunity as fast as possible."

+++

Everyone knows how schools easily transfer any kind of ailment, which subsequently spreads through families.

Kids are the least likely to show symptoms, and their grand parents most likely to be very seriously affected.

More joined up thinking required..

All posters with very low post count:
I read on another board that those with a low post count cannot post links.
Not sure why, or if it is true, but I assume that is the problem this morning. :(

tb1416'

"This morning dip has happened now three or four mornings in a row. MM's making great money out of cautious newbies here."

I suspect that some shares fit the description of
"Don't want to be out of this overnight in case an RNS appears next morning", AVCT being one.
So when no RNS appears, down goes the sp, and cycle repeated @ 16:15.

So not overly concerned now I have rationalised it. ;)

If Boris now has an Antibody test to show for his £1 Mil Mologic investment last month,
I'm sure he will want to put it past the Independent Clinical Performance Evaluation team ASAP,
to see if it performs better than the other 15 products that were tested, - now residing in the scrap container.
Lets hope he gets value for money this time for the 'have I had it' test.

MilkM0NSTA,
Thought your 14:31 post was great.
"The risk that all roads lead to nowhere however are getting smaller day by day."
Yes indeed, and the chances of a buyout by a large Pharma are getting larger by the day.
Any buyout will be predicated on successful development of an Affimer test that is usable on a lateral flow test strip,
but after that I feel AVACTA will possibly be the subject of an auction.

Yes g21, you are correct. - My post header should read
"Costs not included in most posters revenue assumptions"
Thank you for the correction.

From an 18.03.2020 post, after Primerdesign £1M PHE order was confirmed:

https://twitter.com/trade_Fabrice/status/1239877092084457472

17.03.2020 - Jacob Barratt qPCR - Primerdesign Ltd

"I'm happy to announce that after a huge effort from the UK Primerdesign team PHE have trialled our
Covid-19 qPCR detection kit (CE-IVD marked) which performed perfectly.
PHE have placed an initial order for 1,200 kits (thats over 115,000 individual tests) for use in 8 of their
major testing hubs throughout the UK."

115200 / 1200 = 96 tests per test kit, ((COVID-19) genesig® Real-Time PCR assay Instructions for use, confirms 96 tests per kit) https://www.genesig.com/assets/files/Path_Coronavirus_COVID_19_CE_IVD_IFU_Issue_10.pdf?timestamp=1582079599

1200 kits = £1,000,000 order = £833.33 for each test kit.
£833.33 / 96 = £8.68 per test.

++++++

£8.68 / test is what Primerdesign receives for making the test themselves, of which around 80% is profit.

Since then there have been a number of companies that have:
a) made components of the kits (Yourgene)
b) subcontract manufacture of the kit in Dresden (BioType Diagnostic GmbH)
c) Recently announced partners to manufacture kits, who have delivered nothing yet - such as
BioPharma Process Services Ltd, and Biofortuna Limited.

Obviously Primerdesign does not make 80% profit when these companies present their invoices.

Yet many posters are still using £8.68 or are rounding it up to £10 profit / kit.

Please be mindful of the above costs, and also those of the new specialist in rapid process improvement, - Chartwell Consulting.

+++++

16.03.2020 RNS:
Following the completion of Public Health England's (PHE) formal evaluation of Primerdesign's COVID-19 test, as announced on 12 March 2020, the government agency has commenced ordering the test. Orders are initially for eight hospitals to provide stocks in those locations for four weeks of planned testing. The total value of the initial purchase is approximately £1.0 million.
+++++
So we should be hearing more from PHE after the end of the four weeks of planned testing, and any further orders PHE might have.

I think present test kits have a 6 month shelf life, and the proposed changes might adversely affect shelf life.
That won't matter much as presently the kits don't last long after delivery!

Orangutan,
A Parliamentary Petition was organised late last year to"Ban shorting of London AIM stocks".

https://petition.parliament.uk/archived/petitions/242399

I made posters aware on some LSE BB's, and met with pleasure and Angst in equal measure
from those who followed the link.

Under 'more details' you find:

"In challenging times, shorters seek to borrow the company's shares from a holder for a consideration and to buy them at a later date. They immediately sell these shares which, due to the relative illiquid market, sends the price much lower and hence the shorters can buy them at that lower price - pocketing the difference. The only beneficiaries are the shorters and the market makers with the losers being the reputable company and it's bona fide investors."

+++++
Twice this week it has been the case that MM's have dropped the sp after 08:00, to collect shares.
I believe this is to replenish stocks of a scarce share (68 mill in issue and most in sticky hands), and expect this to happen fairly regularly now this ruse has (at least partially) worked for them.
Stand by to see higher highs and lower lows in each days trading methinks.

The 19:57 should have read:

Hi Hants

The same recent RNS also quoted the CEO as saying :

"We are aiming to have developed Affimer reagents for a COVID-19 test by the end of May that can be transferred to Cytiva and potentially to other global diagnostic manufacturers to implement in a test strip".

So for me they have developed the test, they are now working on transferring it to the lateral flow platform,
and their deadline was the end of May, but may be as soon as 2/3 weeks as per this mornings radio broadcast.

Hi Hants'

The same recent RNS also says "Avacta is already generating Affimer reagents that detect the COVID-19 virus",
so I think they already have an Affimer reagent, and are working to make it successful in a lateral flow test strip.

The radio interview today, and indeed the sky news one yesterday was a disappointment.

The CEO has to give some background information about his test and Affimers, and use words the layman has not heard before. This takes most of the time the radio station / sky made available for the interview, before the CEO can start to answer any questions.

You could see the frustration on Alistairs face when cut off by sky news yesterday.

Farcical

23.03.2020 article:

https://www.nature.com/articles/d41587-020-00010-2

This info on SONA literally fell into my lap looking for info on how lateral flow test equipment is approved:

TABLE 1:

SELECTED COMMERCIAL RAPID TESTS FOR SARS-COV-2

Developer: Sona Nanotech (Halifax, Nova Scotia)

Test: Rapid SARS-CoV-2 antigen detection test

Description: Lateral flow screening test for S1 domain of SARS-CoV-2 S1 protein

Status: Assay development and testing with GE Healthcare Life Sciences underway

+++++

So are SONA still in league with GE Healthcare, now Cytiva took over on 01.04.2020 ???

Could the failure of Sona / GE test have been the spur to cause Cytiva to work with Avacta?

I'm expecting +25p ish on sp for each global partner (ala Cytiva), that Avacta signs up.

What approvals are needed for a lateral flow device please.

For a medical device we would need CE Mark, and an FDA EUA.

Is this what we need?

technick, - Sorry I had smilar problems.
Hope this will help :)
https://www.the-scientist.com/the-marketplace/avacta-rapidly-generates-affimer-binders-for-zika-virus-diagnostics-33293

On 11.04.2020 I posted the following:

So as the CEO is quoted as saying the end of May for developing Affimer reagents, I'm going to say the CEO is hedging his bets, and wants to give the company wriggle room, and so expectation is (currently) set at end of May.

But because the RNS also says "Avacta is already generating Affimer reagents that detect the COVID-19 virus", then IMO behind the scenes he has developed a Mark one Affimer reagent.
For me they have let the cat out of the bag with both statements in the one RNS.

++++

This is why Alistair can partake in interviews in the knowledge that a successful affimer test exists.
IMO work continues on how to make the test successful inside a 'lateral flow' test strip.

Nowhere near enough time for Alistair to discuss the subject.
I think the interviewer had time to ask two questions, not more.
Alistair should refuse interviews of less than 10 minutes.

Hi DoneK
A few more factors for your list (good work):

7) Rent for new tissue reprocessing facility which has not been fitted out for tissue processing. - It has freezers temporarily installed.
8) RNS 22.01.2020 -
"As a result of the recruitment of additional new staff, together with subsequent training, we expect this second shift to reach full productivity by the end of H1 2020"

A number of posters here talking of getting a British Standard Kite Mark accreditation, none about CE Mark.

NCYT were the first to get their qPCR test validated via the CE mark, which opens up European and
some Middle East markets.

Isn't the CE mark what we should be aiming at, not the BS Kite mark.

+++++

Can the Affimer test detect Covid-19 presence in an asymptomatic person? - Is there any material
that advises this please?

Its use in the third world looks really good:

1 Result in 10 mins
2 No lab or power supply required
3 Cheap to produce / distribute
4 No interpretation of results required

Start rummaging under the bonnet in the historical RNS's?

we should have something by now I would have thought.
Perhaps the issue is how much else to put with the Saudi news, there is so much more we are waiting for.